spacer
home > ebr > spring 2018 > data swap
PUBLICATIONS
European Biopharmaceutical Review

Data Swap

Biobanks play a significant role in the drug discovery process by providing researchers access to unique sample sets that can be linked to identifying characteristics, which, in turn, can accurately diagnose disease and predict drug response.

Today’s research biobank typically provides physical sample storage and maintains associated data within their databases. Information about acquisition, quality, state, location, processing outcomes, quantity, and usage are all generally available at a minimum, but are primarily focused on the sample characteristics. However, researchers want to link individualities to attributes of the donor, including phenotypical, demographical, genetic, or lifestyle attributes.

A challenge can present itself between the biobank resources and requirements of the research community. The types and amount of data linked to the physical sample that is needed to identify pertinent information can grow more important and complex. Therefore, meeting the expanding specificity of research programmes requires each sample within a biorepository to be connected to as comprehensive a data array as possible to deliver maximum value.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Thurston is Director of Informatics at Brooks Life Sciences, having joined the company in 2015. He has worked in the field of laboratory informatics for over 20 years and has experience in the development, sales, support and marketing of a variety of laboratory software. A graduate of Salford University, UK, with a BSc in chemistry, Colin began his career researching solid-state secondary lithium batteries.
spacer
Colin Thurston
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement